Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Statin-Associated Cardiomyopathy Responds to Statin Withdrawal and Administration of Coenzyme Q10.

Langsjoen PH, Langsjoen JO, Langsjoen AM, Rosenfeldt F.

Perm J. 2019;23. doi: 10.7812/TPP/18.257. Epub 2019 Aug 26.

2.

Response letter to 'does high LDL-cholesterol cause cardiovascular disease?'

Ravnskov U, De Lorgeril M, Diamond DM, Hama R, Hamazaki T, Hammarskjöld B, Hynes N, Kendrick M, Langsjoen PH, Mascitelli L, McCully KS, Okuyama H, Rosch PJ, Schersten T, Sultan S, Sundberg R.

Expert Rev Clin Pharmacol. 2019 Feb;12(2):93-94. doi: 10.1080/17512433.2019.1561102. Epub 2019 Jan 16. No abstract available.

PMID:
30563359
3.

LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature.

Ravnskov U, de Lorgeril M, Diamond DM, Hama R, Hamazaki T, Hammarskjöld B, Hynes N, Kendrick M, Langsjoen PH, Mascitelli L, McCully KS, Okuyama H, Rosch PJ, Schersten T, Sultan S, Sundberg R.

Expert Rev Clin Pharmacol. 2018 Oct;11(10):959-970. doi: 10.1080/17512433.2018.1519391. Epub 2018 Oct 11. Review.

PMID:
30198808
4.

Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review.

Ravnskov U, Diamond DM, Hama R, Hamazaki T, Hammarskjöld B, Hynes N, Kendrick M, Langsjoen PH, Malhotra A, Mascitelli L, McCully KS, Ogushi Y, Okuyama H, Rosch PJ, Schersten T, Sultan S, Sundberg R.

BMJ Open. 2016 Jun 12;6(6):e010401. doi: 10.1136/bmjopen-2015-010401. Review.

5.

Medicines and Vegetable Oils as Hidden Causes of Cardiovascular Disease and Diabetes.

Okuyama H, Langsjoen PH, Ohara N, Hashimoto Y, Hamazaki T, Yoshida S, Kobayashi T, Langsjoen AM.

Pharmacology. 2016;98(3-4):134-70. doi: 10.1159/000446704. Epub 2016 Jun 2. Review.

6.

Erratum. Correction to: Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms.

Okuyama H, Langsjoen PH, Hamazaki T.

Expert Rev Clin Pharmacol. 2015;8(4):503-5. doi: 10.1586/17512433.2015.1055111. Epub 2015 Jun 3. No abstract available.

PMID:
26041341
7.

Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms.

Okuyama H, Langsjoen PH, Hamazaki T, Ogushi Y, Hama R, Kobayashi T, Uchino H.

Expert Rev Clin Pharmacol. 2015 Mar;8(2):189-99. doi: 10.1586/17512433.2015.1011125. Epub 2015 Feb 6. Erratum in: Expert Rev Clin Pharmacol. 2015;8(4):503-5.

PMID:
25655639
8.

Comparison study of plasma coenzyme Q10 levels in healthy subjects supplemented with ubiquinol versus ubiquinone.

Langsjoen PH, Langsjoen AM.

Clin Pharmacol Drug Dev. 2014 Jan;3(1):13-7. doi: 10.1002/cpdd.73. Epub 2013 Oct 8.

PMID:
27128225
9.

Supplemental ubiquinol in patients with advanced congestive heart failure.

Langsjoen PH, Langsjoen AM.

Biofactors. 2008;32(1-4):119-28.

PMID:
19096107
10.

Statin contraindicated in heart failure.

Vos E, Mascitelli L, Langsjoen PH.

Angiology. 2008 Oct-Nov;59(5):640; author reply 641-2. doi: 10.1177/0003319708322389. Epub 2008 Sep 25. No abstract available.

PMID:
18818238
11.

Treatment of statin adverse effects with supplemental Coenzyme Q10 and statin drug discontinuation.

Langsjoen PH, Langsjoen JO, Langsjoen AM, Lucas LA.

Biofactors. 2005;25(1-4):147-52.

PMID:
16873939
12.

Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction.

Silver MA, Langsjoen PH, Szabo S, Patil H, Zelinger A.

Am J Cardiol. 2004 Nov 15;94(10):1306-10.

PMID:
15541254
13.
14.
15.

Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure.

Langsjoen PH.

J Am Coll Cardiol. 2000 Mar 1;35(3):816-7. No abstract available.

16.

Overview of the use of CoQ10 in cardiovascular disease.

Langsjoen PH, Langsjoen AM.

Biofactors. 1999;9(2-4):273-84. Review.

PMID:
10416041
17.

Treatment of hypertrophic cardiomyopathy with coenzyme Q10.

Langsjoen PH, Langsjoen A, Willis R, Folkers K.

Mol Aspects Med. 1997;18 Suppl:S145-51.

PMID:
9266516
18.

Isolated diastolic dysfunction of the myocardium and its response to CoQ10 treatment.

Langsjoen PH, Langsjoen PH, Folkers K.

Clin Investig. 1993;71(8 Suppl):S140-4.

PMID:
8241699
19.

Therapy with coenzyme Q10 of patients in heart failure who are eligible or ineligible for a transplant.

Folkers K, Langsjoen P, Langsjoen PH.

Biochem Biophys Res Commun. 1992 Jan 15;182(1):247-53.

PMID:
1731784
20.

Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy.

Langsjoen PH, Langsjoen PH, Folkers K.

Am J Cardiol. 1990 Feb 15;65(7):521-3. No abstract available.

PMID:
2305693
21.

A six-year clinical study of therapy of cardiomyopathy with coenzyme Q10.

Langsjoen PH, Langsjoen PH, Folkers K.

Int J Tissue React. 1990;12(3):169-71.

PMID:
2276895
22.

Pronounced increase of survival of patients with cardiomyopathy when treated with coenzyme Q10 and conventional therapy.

Langsjoen PH, Folkers K, Lyson K, Muratsu K, Lyson T, Langsjoen P.

Int J Tissue React. 1990;12(3):163-8.

PMID:
2276894
23.

Effective and safe therapy with coenzyme Q10 for cardiomyopathy.

Langsjoen PH, Folkers K, Lyson K, Muratsu K, Lyson T, Langsjoen P.

Klin Wochenschr. 1988 Jul 1;66(13):583-90.

PMID:
3062263
24.

Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10.

Langsjoen PH, Vadhanavikit S, Folkers K.

Proc Natl Acad Sci U S A. 1985 Jun;82(12):4240-4.

25.

Effective treatment with coenzyme Q10 of patients with chronic myocardial disease.

Langsjoen PH, Vadhanavikit S, Folkers K.

Drugs Exp Clin Res. 1985;11(8):577-9.

PMID:
3836875
26.

Cardiovascular complications of total hip replacement.

Langsjoen PH, Murray RA.

Tex Med. 1973 Oct;69(10):75-8. No abstract available.

PMID:
4756547
27.

The value of reducing blood viscosity in acute myocardial infarction.

Langsjoen PH.

Bibl Anat. 1973;11:180-4. No abstract available.

PMID:
4596759
28.

Clinical experience with low molecular weight dextran in acute myocardial infarction.

Langsjoen PH.

J Miss State Med Assoc. 1969 Nov;10(11):499-502. No abstract available.

PMID:
5352795
29.

Studies in the prevention of complications of angiography.

Langsjoen PH, Best EB.

Am J Roentgenol Radium Ther Nucl Med. 1969 Jun;106(2):425-33. No abstract available.

PMID:
4892603
30.

The significance of red cell aggregation in the vascular complications of angiography.

Langsjoen PH, Best EB.

Bibl Anat. 1969;10:449-57. No abstract available.

PMID:
5407399
31.

The treatment of myocardial infarction with low molecular weight dextran.

Langsjoen PH, Sanchez SA, Lynch DJ, Inmon TW.

Am Heart J. 1968 Jul;76(1):28-34. No abstract available.

PMID:
5659273
32.

Hemorrheologic observations in acute myocardial infarction.

Langsjoen PH, Inmon TW.

Angiology. 1968 Apr;19(4):247-56. No abstract available.

PMID:
5647903
33.

Vital rheologic variations in myocardial infarction.

Langsjoen PH.

Biomed Sci Instrum. 1968;4:36-41. No abstract available.

PMID:
5638856
34.

Rheologic changes in myocardial infarction.

Langsjoen PH, Inmon TW.

Am Heart J. 1967 Mar;73(3):430-1. No abstract available.

PMID:
6019202
35.

Electrocardiographic changes during gastric hypothermia.

Garcia AR, Langsjoen PH, Hightower NC Jr.

Dis Chest. 1965 Nov;48(5):497-501. No abstract available.

PMID:
5844580
36.

Acute fatal allergic myocarditis. Report of a case.

Langsjoen PH, Stinson JC.

Dis Chest. 1965 Oct;48(4):440-1. No abstract available.

PMID:
5830929
37.

OBSERVATIONS IN THE EXCRETION OF LOW MOLECULAR DEXTRAN.

LANGSJOEN PH.

Angiology. 1965 Mar;16:148-53. No abstract available.

PMID:
14258333
38.

USE OF LOW MOLECULAR DEXTRAN IN ACUTE MYOCARDIAL INFARCTION.

LANGSJOEN PH.

Tex State J Med. 1965 Feb;61:92-6. No abstract available.

PMID:
14255864
39.

DIFFERENTIATION OF PULMONARY AND CARDIAC BREATHLESSNESS.

LANGSJOEN PH, LYNCH DJ.

Tex State J Med. 1964 Jul;60:556-61. No abstract available.

PMID:
14178302
40.

OBSERVATIONS IN TREATMENT OF ACUTE MYOCARDIAL INFARCTION WITH LOW MOLECULAR DEXTRAN.

LANGSJOEN PH, FALCONER HS, SANCHEZ SA, LYNCH DJ.

Angiology. 1963 Sep;14:465-9. No abstract available.

PMID:
14057647
41.

THE SIGNIFICANCE OF SINUS BRADYCARDIA IN ACUTE MYOCARDIAL INFARCTION.

HADEN RF, LANGSJOEN PH, RAPOPORT MI, MCNERNEY JJ.

Dis Chest. 1963 Aug;44:168-73. No abstract available.

PMID:
14051604
42.

Chest pain of diffuse esophageal spasm simulating disease of the coronary arteries.

LANGSJOEN PH, SALEM ME, HIGHTOWER NC Jr.

Dis Chest. 1963 Apr;43:418-23. No abstract available.

PMID:
13928679
43.

Manifestations of myocardial involvement in acute reactions to penicillin.

HADEN RF, LANGSJOEN PH.

Am J Cardiol. 1961 Sep;8:420-5. No abstract available.

PMID:
13710331
44.

Medical and surgical aspects of open cardiac surgery.

LYTER CS, LANGSJOEN PH.

Mil Med. 1960 Aug;125:532-6. No abstract available.

PMID:
14419210
45.

Cutaneous leishmaniasis: a report of 10 cases.

LANGSJOEN PH.

Ann Intern Med. 1956 Oct;45(4):623-39. No abstract available.

PMID:
13363186
46.

Reflex sympathetic dystrophy without apparent cause.

LANGSJOEN PH, CLEVE EA.

Mil Med. 1955 Oct;117(4):343-7. No abstract available.

PMID:
13253292
47.

The toxic effect of tartar emetic in treatment of schistosomiasis.

CLEVE EA, LANGSJOEN PH, HENSLER NM.

Am J Med Sci. 1955 Jan;229(1):74-80. No abstract available.

PMID:
13218027

Supplemental Content

Loading ...
Support Center